A total of 539 patients were enrolled in this study; 527 patients with HER2-negative GC who received nivolumab plus chemotherapy as first line treatment were included in this analysis, excluding those who did not meet the eligibility criteria (Online Resource 4). This evidence concerns the gene ERBB2 and gastric cancer.